VT301 / ViThera - LARVOL DELTA

A preclinical and phase I clinical study of ex vivo-expanded amyloid beta-specific human regulatory T cells in Alzheimer's disease. (PubMed, Biomed Pharmacother) - P1 | "This study suggests that hTregs may modulate Alzheimer's disease pathology by suppressing neuroinflammation, while VT301 shows promise as a safe treatment option. However, further research is necessary to confirm its clinical efficacy and optimize treatment strategies."

Journal • P1 data • Preclinical • Alzheimer's Disease • CNS Disorders • Inflammation

A NOVEL THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE USING AMYLOID ΒETA-SPECIFIC HUMAN REGULATORY T CELLS TO CONTROL MICROGLIA ACTIVATION IN 3XTG MOUSE BRAIN. (ADPD 2022) - "Here we confirm whether expanded amyloid-beta (Aβ)-specific Tregs with bvPLA2 in vitro (designated Ag-hTreg, VT301) exhibits efficacy as a therapeutic agent for neuro-inflammation. Therefore, our finding opens up the possibility of the clinical application using Treg as a cell therapy for Alzheimer's disease or microglia-related neuroinflammatory diseases."

Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • Depression • Immunology • Inflammation • Psychiatry • CD4 • FOXP3 • IL2RA

A Study of Possibility of Using Regulatory T Cells(VT301) for Treatment of Alzheimer's Disease (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: VTBIO Co. LTD

Clinical • New P1 trial • Alzheimer's Disease • CNS Disorders

Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 (clinicaltrials.gov) - P2b; N=7; Not yet recruiting; Sponsor: Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company; Initiation date: Mar 2019 ➔ Aug 2019

Clinical • Trial initiation date

Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 (clinicaltrials.gov) - P2b; N=7; Not yet recruiting; Sponsor: Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company

Clinical • New P2b trial